Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis
He Li,Lihui Xie,Lei Zhu,Zhaohuai Li,Rong Wang,Xiuxing Liu,Zhaohao Huang,Binyao Chen,Yuehan Gao,Lai Wei,Chang He,Rong Ju,Yizhi Liu,Xialin Liu,Yingfeng Zheng,Wenru Su
DOI: https://doi.org/10.1038/s41467-022-33502-7
IF: 16.6
2022-10-04
Nature Communications
Abstract:Abstract Uveitis is a severe autoimmune disease, and a common cause of blindness; however, its individual cellular dynamics and pathogenic mechanism remain poorly understood. Herein, by performing single-cell RNA sequencing (scRNA-seq) on experimental autoimmune uveitis (EAU), we identify disease-associated alterations in cell composition and transcriptional regulation as the disease progressed, as well as a disease-related molecule, PIM1. Inhibiting PIM1 reduces the Th17 cell proportion and increases the Treg cell proportion, likely due to regulation of PIM1 to the protein kinase B (AKT)/Forkhead box O1 (FOXO1) pathway. Moreover, inhibiting PIM1 reduces Th17 cell pathogenicity and reduces plasma cell differentiation. Importantly, the upregulation of PIM1 in CD4 + T cells and plasma cells is conserved in a human uveitis, Vogt-Koyanagi-Harada disease (VKH), and inhibition of PIM1 reduces CD4 + T and B cell expansion. Collectively, a dynamic immune cellular atlas during uveitis is developed and implicate that PIM1 may be a potential therapeutic target for VKH.
multidisciplinary sciences